Literature DB >> 16038799

Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK.

Hiroyuki Kobayashi1, Yusuke Narita, Motohiro Nishida, Hitoshi Kurose.   

Abstract

Beta-arrestin mediates desensitization and internalization of beta-adrenergic receptors (betaARs), but also acts as a scaffold protein in extracellular signal-regulated kinase (ERK) cascade. Thus, we have examined the role of beta-arrestin2 in the betaAR-mediated ERK signaling pathways. Isoproterenol stimulation equally activated cytoplasmic and nuclear ERK in COS-7 cells expressing beta1AR or beta2AR. However, the activity of nuclear ERK was enhanced by co-expression of beta-arrestin2 in beta2AR-but not beta1AR-expressing cells. Pertussis toxin treatment and blockade of Gbetagamma action inhibited beta-arrestin2-enhanced nuclear activation of ERK, suggesting that beta-arrestin2 promotes nuclear ERK localization in a Gbetagamma dependent mechanism upon receptor stimulation. beta2AR containing the carboxyl terminal region of beta1AR lost the beta-arrestin2-promoted nuclear translocation. As the carboxyl terminal region is important for beta-arrestin binding, these results demonstrate that recruitment of beta-arrestin2 to carboxyl terminal region of beta2AR is important for ERK localization to the nucleus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038799     DOI: 10.1016/j.cellsig.2004.12.014

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  18 in total

Review 1.  Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction.

Authors:  K Defea
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

2.  β-arrestin-2 regulation of the cAMP response element binding protein.

Authors:  Mary E Manson; Deborah A Corey; Sharon M Rymut; Thomas J Kelley
Journal:  Biochemistry       Date:  2011-06-15       Impact factor: 3.162

3.  Okadaic acid induces matrix metalloproteinase-9 expression in fibroblasts: crosstalk between protein phosphatase inhibition and β-adrenoceptor signalling.

Authors:  A Rietz; Y Volkov; A Davies; M Hennessy; J P Spiers
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  Modulating micro-opioid receptor phosphorylation switches agonist-dependent signaling as reflected in PKCepsilon activation and dendritic spine stability.

Authors:  Hui Zheng; Ji Chu; Yuhan Zhang; Horace H Loh; Ping-Yee Law
Journal:  J Biol Chem       Date:  2011-02-03       Impact factor: 5.157

Review 5.  Ligand-directed signalling at beta-adrenoceptors.

Authors:  Bronwyn A Evans; Masaaki Sato; Mohsin Sarwar; Dana S Hutchinson; Roger J Summers
Journal:  Br J Pharmacol       Date:  2010-02-02       Impact factor: 8.739

Review 6.  Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications.

Authors:  Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  IUBMB Life       Date:  2010-02       Impact factor: 3.885

7.  beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation.

Authors:  Supachoke Mangmool; Arun K Shukla; Howard A Rockman
Journal:  J Cell Biol       Date:  2010-04-26       Impact factor: 10.539

8.  GPR54 regulates ERK1/2 activity and hypothalamic gene expression in a Gα(q/11) and β-arrestin-dependent manner.

Authors:  Jacob M Szereszewski; Macarena Pampillo; Maryse R Ahow; Stefan Offermanns; Moshmi Bhattacharya; Andy V Babwah
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms.

Authors:  Jamie Rose Kuhar; Andrea Bedini; Erica J Melief; Yen-Chen Chiu; Heather N Striegel; Charles Chavkin
Journal:  Cell Signal       Date:  2015-06-05       Impact factor: 4.315

10.  Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation.

Authors:  Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  Mol Pharmacol       Date:  2007-10-18       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.